ABSTRACT
pharmacokinetics of these agents in pediatric patients. This study evaluated the effects of body 28 size and gender on the pharmacokinetics of artesunate/DHA using data from pediatric and adult 29 malaria patients. Nonlinear mixed effects modeling was used to obtain a base model consisting 30 of first-order artesunate absorption and one-compartment models for artesunate and for DHA. respectively. Estimates for the linear BSA model were similar. The 95% confidence intervals 36 for the estimated gender effects on clearance and volume parameters for artesunate fell outside 37 the pre-defined no relevant clinical effect interval of 0.75 -1.25. However, the effect of gender 38 on apparent DHA clearance was almost entirely contained within this interval, suggesting a lack 39 of influence of gender on this parameter. Overall, the pharmacokinetics of artesunate and DHA 40 following oral artesunate can be described for pediatric patients using either an allometric scaling 41 or linear BSA model. Both models predict that, for a given mg/kg artesunate dose, younger A summary of patient demographics for included clinical trials is given in Table 1. In all   94 five trials, patients were administered PA once daily for three days without regard to food intake.
95
In the Phase II study (Study 1), plasma samples were collected prior to the first dose of PA, and 96 at 0.25, 0.5, 1, 1.5, 2.5, 4, 8, 12 hours following that dose; patients were administered 2, 3, or 4 97 mg/kg/day artesunate (7). In the Phase III studies, one sample was drawn during a 0. younger had LBM1 set to equal total body weight.
200
The second lean body mass estimation approach followed the method proposed by Peters pediatric ECV estimation formula described by Bird et al. (18 body size descriptor was used on all clearance and volume parameters in any given model. All 219 models were evaluated using both the full and pediatric datasets.
220
The models incorporating body size descriptors as described above were evaluated per 221 multiple criteria in order to identify a model to be carried forward for subsequent analyses.
222
These criteria included the following: developmental and physiologic plausibility of the estimated parameters). to these datasets. This process was then repeated using the pediatric dataset. The distributions 246 for the covariate effect estimates were then plotted using the metrumrg R package (21).
Predictive checks

249
After the full covariate models for both the full and pediatric datasets were obtained, with the gender effects estimated on the clearance and volume parameters, are given in Table 4 343 for the allometric scaling and the linear BSA models, with analogous parameter estimates from 344 the full population models given in Table S3 . IIV covariance estimates for the various models 345 are given in Table S4 . The 95% confidence intervals for the effects, determined through 500 indicative of efficient esterase activity for patients at, and even prior to, one year of age (26, 27). Table 3 . Body size models estimated using both full and pediatric datasets. 
